貨號(hào)：GS40488

Ocrelizumab is a humanized, anti?CD20 monoclonal antibody of the IgG1 isotype. It targets CD20, a cell?surface protein expressed on mature B cells. Compared to earlier anti?CD20 antibodies, ocrelizumab is engineered with a humanized Fc portion designed to enhance antibody?dependent cellular cytotoxicity (ADCC) while reducing complement?dependent cytotoxicity (CDC). It depletes circulating CD20?positive B cells while preserving stem cells and plasma cells. It is approved for the treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), making it the first therapy approved for PPMS. It is administered via intravenous infusion every six months.